The Food and Drug Administration approved mirvetuximab soravtansine-gynx, or Elahere, from ImmunoGen, now a part of AbbVie, for adult patients with FRalpha positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. Patients are selected based on an FDA-approved test. Mirvetuximab soravtansine-gynx previously received accelerated approval for this indication, the FDA noted.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- JPMorgan biotech/pharma analysts hold an analyst/industry conference call
- Allergan Aesthetics announces FDA approval of JUVEDERM VOLUMA XC
- AbbVie makes milestone payment to Dragonfly after dosing in solid tumor trial
- AbbVie, OSE Immunotherapeutics enter pact to develop OSE-230
- Regenxbio expects cash to fund operations into 2H25
